PureTech Health PLC

PRTC

17.300USD

-0.010-0.06%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

189 / 506

Overall Ranking

287 / 4718

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

46.000

Target Price

+171.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.83M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 53.51M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is 82.32, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 335.52K shares, decreasing 15.99% quarter-over-quarter.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93. Its latest quarterly revenue reached 4.54M, representing a year-over-year increase of 2422.22%, while its net profit experienced a year-over-year increase of 334.15%.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.93, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 69.90, which is 83.67% below the recent high of 128.39 and -35.35% above the recent low of 94.62.

Score

Industry at a Glance

Previous score

6.78

Change

1.17

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 189/506

No Data

The company’s current earnings forecast score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for PureTech Health PLC is 53.25, with a high of 60.50 and a low of 46.00.

Score

Industry at a Glance

Previous score

10.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 5.48, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 18.06 and the support level at 12.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.64

Change

0.27

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-09-24

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Birch Hill Investment Advisors LLC

302.00K

--

Pentwater Capital Management LP

33.56K

+39.19%

Portolan Capital Management, L.L.C.

11.88K

--

Millennium Management LLC

44.91K

-0.78%

Fidelity Management & Research Company LLC

1.28K

--

Geode Capital Management, L.L.C.

770.00

--

Dimensional Fund Advisors, L.P.

316.00

-39.69%



1

2



The company’s current risk assessment score is 4.04, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

PureTech Health PLC

PRTC

5.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.01 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MiMedx Group Inc

MDXG

7.88 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Soleno Therapeutics Inc

SLNO

7.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

ACADIA Pharmaceuticals Inc

ACAD

7.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment